HCA vs THC vs EHC
161 measures in 16 categories, one definition each, computed from filings and market data.
HCA53.6
HCA Healthcare, Inc.
Healthcare · Medical - Care Facilities
$458.84 −2.10%$99.3B mkt cap
Score DNA
THC63.3
Tenet Healthcare Corporation
Healthcare · Medical - Care Facilities
$267.25 −2.86%$21.5B mkt cap
Score DNA
EHC64.4
Encompass Health Corporation
Healthcare · Medical - Care Facilities
$127.87 +0.10%$12.6B mkt cap
Score DNA
Price, rebased to 100 three years ago
HCA THC EHC · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 8 | 0 | 0 |
| Last Congress purchase | 2026-09-04 | — | — |
| 13F net change in holders | −79 | — | — |
| ETFs adding shares, 30d | 1,032 | 370 | 332 |
| ETFs trimming, 30d | 1,005 | 414 | 262 |
| Net ETF funds, 30d | +27 | −44 | +70 |
Valuation
16 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| P/E (TTM) | 14.5x
35th
|
9.6x
9th
|
20.3x
43rd
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 1.04
69th
|
0.12
0th
|
0.78
46th
|
| Price / sales | 1.3x
53rd
|
1.0x
38th
|
2.0x
81st
|
| Price / book | — | 4.6x
68th
|
4.9x
71st
|
| Price / tangible book | — | — | 10.4x
69th
|
| Price / free cash flow | 16.6x
56th
|
7.1x
11th
|
30.5x
85th
|
| Price / operating cash flow | 8.9x
31st
|
5.4x
14th
|
10.4x
45th
|
| Enterprise value | $147.1B
100th
|
$32.6B
97th
|
$15.3B
88th
|
| EV / sales | 1.9x
69th
|
1.5x
41st
|
2.5x
84th
|
| EV / EBITDA | 9.3x
43rd
|
6.4x
18th
|
10.2x
46th
|
| EV / EBIT | 12.1x
33rd
|
7.8x
15th
|
13.3x
37th
|
| EV / free cash flow | 24.5x
63rd
|
10.8x
19th
|
37.1x
89th
|
| Earnings yield | 6.9%
75th
|
10.4%
94th
|
4.9%
69th
|
| FCF yield | 6.0%
53rd
|
14.0%
91st
|
3.3%
28th
|
| Operating cash flow yield | 11.2%
72nd
|
18.7%
88th
|
9.6%
59th
|
| Graham number (per share) | — | $182.52
95th
|
$60.25
67th
|
Profitability (TTM)
12 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| Gross margin | 28.4%
53rd
|
26.9%
47th
|
43.9%
84th
|
| EBITDA margin | 20.3%
84th
|
23.2%
91st
|
24.2%
94th
|
| Operating margin | 15.5%
88th
|
16.8%
91st
|
18.0%
94th
|
| EBIT margin | 15.6%
81st
|
19.1%
94th
|
18.6%
88th
|
| Net margin | 8.8%
75th
|
10.3%
88th
|
10.0%
84th
|
| NOPAT margin | 12.3%
84th
|
13.8%
88th
|
14.3%
91st
|
| FCF margin | 7.7%
59th
|
13.9%
94th
|
6.7%
50th
|
| Operating cash flow margin | 14.3%
78th
|
18.4%
91st
|
19.5%
94th
|
| R&D / revenue | 0.0%
0th
|
0.0%
0th
|
0.0%
0th
|
| SG&A / revenue | 21.2%
81st
|
30.3%
88th
|
17.3%
59th
|
| Stock comp / revenue | 0.0%
0th
|
0.4%
23rd
|
0.9%
53rd
|
| Effective tax rate | 20.4%
16th
|
17.9%
3rd
|
20.5%
19th
|
Returns on capital
11 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| ROE (on average equity) | — | 53.3%
97th
|
25.5%
76th
|
| ROA | 11.4%
81st
|
7.5%
66th
|
8.7%
72nd
|
| ROIC | 23.3%
84th
|
19.1%
78th
|
16.7%
72nd
|
| ROCE | 29.4%
91st
|
16.6%
75th
|
17.5%
81st
|
| Return on tangible assets | 20.3%
88th
|
14.0%
72nd
|
16.2%
81st
|
| Cash ROIC (OCF / invested capital) | 27.0%
78th
|
25.5%
69th
|
22.7%
62nd
|
| Gross profitability (GP / assets) | 36.5%
59th
|
19.1%
28th
|
49.0%
84th
|
| ROIC, 3-yr average | 16.4%
96th
|
13.7%
86th
|
10.6%
82nd
|
| ROIC, 5-yr average | — | 11.1%
87th
|
9.9%
83rd
|
| ROE, 5-yr average | — | 56.9%
100th
|
21.2%
91st
|
| Incremental ROIC | — | 182.3%
71st
|
99.7%
58th
|
Growth
17 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| Revenue growth (TTM YoY) | 7.3%
44th
|
5.4%
28th
|
9.5%
47th
|
| Revenue growth (QoQ) | 5.9%
75th
|
4.8%
69th
|
0.7%
16th
|
| Revenue CAGR, 3 yr | 8.0%
29th
|
3.1%
11th
|
10.7%
46th
|
| Revenue CAGR, 5 yr | 6.8%
31st
|
2.6%
12th
|
4.8%
27th
|
| Gross profit CAGR, 3 yr | 33.5%
88th
|
-7.3%
8th
|
5.6%
28th
|
| Operating income CAGR, 3 yr | 9.1%
42nd
|
16.1%
63rd
|
-1.7%
16th
|
| Net income growth (TTM YoY) | 14.6%
28th
|
51.0%
72nd
|
18.8%
39th
|
| Net income CAGR, 3 yr | 5.8%
20th
|
65.0%
100th
|
25.5%
67th
|
| EPS growth (TTM YoY) | 24.4%
44th
|
65.1%
78th
|
21.4%
39th
|
| EPS CAGR, 3 yr | 14.0%
27th
|
77.6%
100th
|
26.0%
60th
|
| EPS CAGR, 5 yr | 15.5%
64th
|
46.2%
100th
|
10.1%
36th
|
| FCF growth (TTM YoY) | -17.8%
8th
|
93.4%
81st
|
-5.9%
19th
|
| FCF CAGR, 3 yr | 6.7%
29th
|
46.5%
82nd
|
53.7%
88th
|
| Operating cash flow CAGR, 3 yr | 4.2%
26th
|
31.1%
74th
|
21.4%
52nd
|
| Book value CAGR, 3 yr | — | 63.0%
95th
|
21.2%
82nd
|
| Dividend CAGR, 3 yr | 7.5%
78th
|
— | 4.3%
67th
|
| Sustainable growth rate | — | 53.3%
95th
|
22.4%
62nd
|
Margin history & stability
7 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| Gross margin, 3-yr average | 19.5%
24th
|
39.1%
72nd
|
47.5%
86th
|
| Operating margin, 3-yr average | 15.2%
86th
|
20.0%
93rd
|
20.2%
97th
|
| Net margin, 3-yr average | 8.5%
90th
|
10.2%
97th
|
9.0%
93rd
|
| FCF margin, 3-yr average | 8.3%
72nd
|
10.1%
90th
|
6.2%
59th
|
| Revenue stability (0-1) | 0.98
93rd
|
0.91
41st
|
0.66
14th
|
| Earnings stability (0-1) | 0.40
62nd
|
0.54
79th
|
0.68
83rd
|
| Margin stability (0-1) | 0.68
21st
|
0.77
31st
|
0.64
14th
|
Liquidity (latest quarter)
7 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| Cash & short-term investments | $1.0B
97th
|
$2.2B
100th
|
$107.7M
28th
|
| Net cash (− = net debt) | −$47.8B
0th
|
−$11.1B
3rd
|
−$2.7B
22nd
|
| Working capital | −$4.2B
0th
|
$2.3B
100th
|
$167.6M
59th
|
| Current ratio | 0.78
0th
|
1.41
62nd
|
1.19
38th
|
| Quick ratio | 0.69
0th
|
1.35
62nd
|
1.19
41st
|
| Cash ratio (cash + ST investments / current liabilities) | 0.05
3rd
|
0.39
53rd
|
0.12
12th
|
| Defensive interval (days) | 483 days
58th
|
794 days
74th
|
114 days
10th
|
Leverage & solvency (latest quarter)
13 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| Total debt | $48.8B
100th
|
$13.2B
97th
|
$2.8B
78th
|
| Debt / equity | — | 2.84
86th
|
1.09
61st
|
| Net debt / equity | — | 2.38
89th
|
1.05
64th
|
| Debt / assets | 80.6%
97th
|
43.2%
69th
|
38.1%
53rd
|
| Debt / capital | — | 74.0%
86th
|
52.2%
61st
|
| Debt / EBITDA | 3.08
57th
|
2.62
46th
|
1.89
32nd
|
| Net debt / EBITDA | 3.02
61st
|
2.19
50th
|
1.82
43rd
|
| Interest coverage (EBIT / interest) | 5.3x
47th
|
5.1x
43rd
|
9.2x
63rd
|
| Cash interest coverage | 4.8x
37th
|
4.9x
40th
|
9.7x
50th
|
| Debt payback (years of OCF) | 4.4 yrs
55th
|
3.3 yrs
45th
|
2.3 yrs
34th
|
| Liabilities / assets | 105.2%
97th
|
71.6%
69th
|
53.6%
38th
|
| IS credit model rating | BBB- | BBB | A |
| Implied credit spread (bps) | 350
59th
|
275
53rd
|
150
31st
|
Efficiency
11 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| Asset turnover | 1.30
66th
|
0.73
19th
|
0.87
31st
|
| Fixed asset turnover | 2.29
19th
|
3.49
48th
|
1.37
16th
|
| Inventory turnover | 32.4
47th
|
47.2
60th
|
— |
| Receivables turnover | 6.9
16th
|
8.5
41st
|
9.5
56th
|
| Days sales outstanding | 53 days
84th
|
43 days
59th
|
38 days
44th
|
| Days inventory outstanding | 11 days
56th
|
8 days
44th
|
— |
| Days payables outstanding | 29 days
62nd
|
31 days
69th
|
28 days
56th
|
| Cash conversion cycle (days) | 35 days
81st
|
20 days
47th
|
10 days
22nd
|
| Capex / revenue | 6.6%
81st
|
4.5%
71st
|
12.9%
100th
|
| Capex / depreciation | 1.40
81st
|
1.11
71st
|
2.31
94th
|
| Operating expense ratio | 0.0%
0th
|
0.0%
0th
|
26.5%
72nd
|
Cash flow & earnings quality
7 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| Operating cash flow / net income | 1.63
48th
|
1.79
65th
|
1.95
70th
|
| FCF / net income | 0.88
22nd
|
1.35
52nd
|
0.67
13th
|
| FCF / operating cash flow | 53.9%
29th
|
75.3%
50th
|
34.1%
14th
|
| Capex / operating cash flow | 46.1%
71st
|
24.7%
50th
|
65.9%
86th
|
| Accruals ratio | -7.1%
44th
|
-6.0%
56th
|
-8.3%
25th
|
| Sloan accruals ratio | -12.5%
12th
|
-5.6%
34th
|
-3.3%
44th
|
| Earnings quality score (0-1) | 0.75
9th
|
0.75
9th
|
0.75
9th
|
Scores & forensic checks
15 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| IS score | 54
41st
|
63
69th
|
64
72nd
|
| IS profitability | 32
50th
|
56
81st
|
61
94th
|
| IS growth | 66
59th
|
66
56th
|
61
38th
|
| IS value | 65
78th
|
67
88th
|
57
66th
|
| IS momentum | 83
47th
|
88
66th
|
87
56th
|
| IS risk (safety) | 65
44th
|
50
19th
|
80
56th
|
| IS quality | 60
47th
|
61
50th
|
80
88th
|
| IS balance sheet | 29
19th
|
36
34th
|
55
56th
|
| IS earnings quality | 70
47th
|
76
66th
|
72
50th
|
| IS cash flow | 45
34th
|
69
75th
|
45
38th
|
| Piotroski F-score (0-9) | 6
34th
|
7
59th
|
9
97th
|
| Altman Z-score | 2.5
44th
|
1.9
22nd
|
3.2
62nd
|
| Beneish M-score | −2.64
47th
|
−1.11
88th
|
−2.75
31st
|
| Ohlson O-score | −7.23
47th
|
−7.49
38th
|
−8.11
31st
|
| IS credit score | 52
34th
|
59
44th
|
72
62nd
|
Size (TTM)
8 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| Market cap | $99.3B
100th
|
$21.5B
97th
|
$12.6B
94th
|
| Revenue | $78.0B
100th
|
$21.8B
94th
|
$6.2B
81st
|
| EBITDA | $15.8B
100th
|
$5.1B
97th
|
$1.5B
84th
|
| Net income | $6.8B
100th
|
$2.2B
97th
|
$621.0M
88th
|
| Free cash flow | $6.0B
100th
|
$3.0B
97th
|
$413.4M
81st
|
| Total assets | $60.5B
100th
|
$30.7B
97th
|
$7.5B
81st
|
| Shareholders' equity | −$6.6B
0th
|
$4.7B
97th
|
$2.6B
94th
|
| Employees | 320,000
100th
|
88,500
94th
|
29,699
66th
|
Price performance
9 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| 1 day | −2.1% | −2.9% | +0.1% |
| 1 week | +1.7% | +1.3% | +3.7% |
| 1 month | +6.9% | +2.0% | +4.0% |
| 3 months | +23.8% | +37.5% | +13.7% |
| 6 months | −6.0% | +35.9% | +20.2% |
| Year to date | −2.5% | +34.0% | +20.2% |
| 1 year | +9.3% | +34.1% | +3.4% |
| 3 years, cumulative | +91.2% | +363.2% | +101.9% |
| 5 years, cumulative | +97.9% | +332.0% | +135.9% |
Technicals
4 measures| Measure | HCA | THC | EHC |
|---|---|---|---|
| RSI 14 | 62.9 | 55.0 | 66.3 |
| From 52-week high | −17.5% | −5.6% | −1.6% |
| From 52-week low | +29.6% | +69.6% | +37.9% |
| Beta | 1.11 | 1.20 | 0.61 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17